YD Bio Limited Ordinary Shares
YDES · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -622.68 | -0.97 | -0.05 |
| FCF Yield | -9.51% | -0.01% | -2.70% | -0.39% |
| EV / EBITDA | -36.54 | 37,935.32 | 29.52 | 20.24 |
| Quality | ||||
| ROIC | -22.49% | -10.72% | -18.75% | -1.48% |
| Gross Margin | 30.44% | 43.83% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.30 | -4.10 | -0.80 | -0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -8,386.27% | 98.15% | -339.08% | -171.44% |
| Safety | ||||
| Net Debt / EBITDA | 2.43 | -1.78 | -0.00 | -0.00 |
| Interest Coverage | -1,893.69 | -4.59 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 9.51 | 2.83 | 0.00 | 0.00 |
| Cash Conversion Cycle | 198.84 | 198.05 | 0.00 | 0.00 |